Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/gtmb.2015.29001.kje | DOI Listing |
Arterioscler Thromb Vasc Biol
January 2025
Cardiovascular Research Center, New York University Langone Health, New York University Grossman School of Medicine. (A.A.C.N., J.M.D., K.J.M.).
The field of cardio-oncology has traditionally focused on the impact of cancer and its therapies on cardiovascular health. Mounting clinical and preclinical evidence, however, indicates that the reverse may also be true: cardiovascular disease can itself influence tumor growth and metastasis. Numerous epidemiological studies have reported that individuals with prevalent cardiovascular disease have an increased incidence of cancer.
View Article and Find Full Text PDFChildren (Basel)
October 2024
Department of Psychology and Sociology, University of Zaragoza, 44003 Teruel, Spain.
J Cereb Blood Flow Metab
November 2024
Institute of Neurobiology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Brain pH is precisely regulated, and pH transients associated with activity are rapidly restored under physiological conditions. During ischemia, the brain's ability to buffer pH changes is rapidly depleted. Tissue oxygen deprivation causes a shift from aerobic to anaerobic metabolism and the accumulation of lactic acid and protons.
View Article and Find Full Text PDFFront Immunol
October 2024
Gastroenterology Unit, ASST Fatebenefratelli-Sacco, Milano, Italy.
Cardiovasc Drugs Ther
December 2024
Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Viale Pieraccini 6, Florence, Italy.
Polypharmacy is often necessary in complex, chronic, comorbid and cardiovascular patients and is a known risk factor for potential drug-drug interaction (DDI) that can cause adverse reactions (toxicity or therapeutic failure). Anti-thrombotic drugs (largely low-dose aspirin and a platelet P2Y12 receptor inhibitor) and statins are among the most co-administered drugs in cardiovascular patients. Ticagrelor is a selective antagonist of the platelet P2Y12-receptor, highly effective in inhibiting platelet aggregation and bio-transformed by the CYP3A4 and substrate of transporters, such as the breast cancer resistance protein (BCRP).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!